Skip to main content
OpenTrials
Completed

NCT Number: NCT00660868

Is Pentoxifylline Able to Improve Olfactory Sensitivity?

Signal processing in the olfactory neuron could be influenced by inhibition of enzymes like phosphodiesterase. Pentoxifylline is a unspecific phosphodiesterase inhibitor. The hypothesis is that pentoxifylline could lead to increased sensitivity to odors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Olfaction Disorders Anosmia Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Sensation Disorders Signs and Symptoms

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zentrum für Riechen und Schmecken, Universitäts- HNO- Klinik Dresden

Dresden, 01307, Germany

About this study

Olfactory signal processing is conducted by a G-protein linked increase of intracellular concentration of adenosine 3´,5´-cyclic monophosphate (cAMP). In the cilia of olfactory sensory neurons (OSN) cAMP is degraded by phosphodiesterase 1C2 (PDE1C2). Inhibition of PDE1C2 could result in an increased response of OSN to chemical stimuli. Aim of the present prospective post-marketing surveillance study was to investigate the impact of pentoxifylline, an unspecific phosphodieasterase inhibitor, on olfactory function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hyposmic or functionally anosmic patients TDI-score <31
  • age: 18-50 years
  • odor threshold: better than 1
  • cause of smell loss: post traumatic, postinflammatory, idiopathic

Exclusion criteria

  • normosmic patients,
  • patients with contraindications for application of pentoxifylline
  • patients that cannot give written agreement to the study
  • patients under 18 years and over 50 years of age

Treatment and study plan

Pentoxifylline retard 400mg

Drug

Agapurin retard 400mg 3/day per os for 3 weeks

Other names: Agapurin retard

Primary outcomes

  1. TDI-score

    Time frame: at day 0 and follow up after 3 weeks

Secondary outcomes

  1. odor threshold odor discrimination odor identification

    Time frame: at day 0 and at follow up after 3 weeks

Sponsors and collaborators

Lead sponsor

Technische Universität Dresden

Other

Registry information

Official study title

Agapurin Retard Used in Patients With Smell Disorder- A Post-marketing Observational Study

Important dates

Study start
2009
Primary completion
2016
Study completion
2016
First posted
Apr 17, 2008
Registry last updated
Feb 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.